$3.36
3.17%
Nasdaq, Aug 29, 10:17 pm CET
ISIN
US04683R1068
Symbol
AVIR

Atea Pharmaceuticals Inc Stock price

$3.36
-0.44 11.58% 1M
+0.33 10.89% 6M
+0.01 0.30% YTD
-0.42 11.11% 1Y
-4.38 56.59% 3Y
-26.98 88.93% 5Y
-26.98 88.93% 10Y
-26.98 88.93% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.11 3.17%
ISIN
US04683R1068
Symbol
AVIR
Industry

Key metrics

Basic
Market capitalization
$266.6m
Enterprise Value
$-113.1m
Net debt
positive
Cash
$379.7m
Shares outstanding
81.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
1.0
P/B
0.7
Financial Health
Equity Ratio
94.5%
Return on Equity
-38.3%
ROCE
-39.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-145.1m | $-139.9m
EBIT
$-145.5m | $-260.1m
Net Income
$-136.1m | $-142.4m
Free Cash Flow
$-116.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-15.5% | -6.3%
EBIT
-15.4% | -97.1%
Net Income
22.8% | 15.3%
Free Cash Flow
3.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.4
Short interest
7.9%
Employees
56
Rev per Employee
$0.0
Show more

Is Atea Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Atea Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Atea Pharmaceuticals Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Atea Pharmaceuticals Inc forecast:

Buy
75%
Hold
25%

Financial data from Atea Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 43 43
11% 11%
-
- Research and Development Expense 103 103
34% 34%
-
-145 -145
15% 15%
-
- Depreciation and Amortization 0.41 0.41
5% 5%
-
EBIT (Operating Income) EBIT -145 -145
15% 15%
-
Net Profit -136 -136
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Atea Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atea Pharmaceuticals Inc Stock News

Neutral
Seeking Alpha
24 days ago
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrea J. Corcoran - CFO, Executive VP of Legal & Secretary Janet M.
Neutral
The Motley Fool
25 days ago
Atea (AVIR) Q2 Loss Narrows 8%
Neutral
GlobeNewsWire
25 days ago
Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV  Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration Regimen of Bemnifosbuvir/Ruzasvir has Potential Best-in-Class Profile with Short Tre...
More Atea Pharmaceuticals Inc News

Company Profile

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Head office United States
CEO Jean-Pierre Sommadossi
Employees 56
Founded 2012
Website ateapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today